Free Newsletter
Allergan eyes billion-dollar mascara market
Free newsletter via e-mail
Tools
Move over mascara. Allergan announced today that it will be filing a new drug application for bimatoprost, a drug that it claims encourages eyelash growth. It expects sales in excess of $500 million per year--modest expectations in light of the estimated $3.7 billion per year mascara market. Allergan makes Lumigan, a glaucoma remedy that had the unusual added benefit of promoting eyelash growth. Some doctors were prescribing it off-lable for its cosmetic use, and Allergan has struck out at cosmetic companies for producing an OTC products they say are based partly on Lumigan ingredients.
Bimatoprost, a synthetic prostaglandin analog, results in eyelash growth that is significant when applied directly to the eyelash bases, according to Allergan's clinical trials. The company expects FDA to approve the drug in 2009.
- read the news in the WSJ
- see MarketWatch for more
Related Articles:
Allergan, FDA fight eyelash-mad copycats
Allergan wins FDA OK for new therapy
Allergan injects $370M into Esprit buyout
Comments
By Alice Hopkins | Posted 2:26pm | January 26, 2009
I am an instructor at two universities in Indianaolis. One of my students has glaucoma. She treats her glaucoma with drops, and she has the longest, prettiest eyelashes. I believe you! Please send me information ASAP when this is marketed. Incidentally, I have glaucoma in my family, so I am hoping for the best when I go see my opthamologist.
By tina | Posted 4:43pm | January 29, 2009
how do you get to participate in one of their clinical studies in nc?
By Nancy | Posted 9:30am | June 3, 2009
It sounds great, please email when it would be available.
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
